Argentina vs Nepal: Average cost of multi drug-resistant tuberculosis treatment
Argentina
1,547 constant 2022 US$
in 2024
Nepal
1,526 constant 2022 US$
in 2024
Argentina rank
31st
Nepal rank
33rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Argentina
- Nepal
How they compare
Argentina currently reports 1,547 constant 2022 US$ against 1,526 constant 2022 US$ in Nepal, a difference of 21 constant 2022 US$.
The two have swapped places 5 times across 7 shared years of data; in 2018 it was Nepal ahead.
Argentina ranks 31st and Nepal ranks 33rd of 92 countries.
Argentina has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Argentina | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,552 constant 2022 US$ | 1,165 constant 2022 US$ | 387 constant 2022 US$ | Argentina |
| 2020s | 1,334 constant 2022 US$ | 1,226 constant 2022 US$ | 108.2 constant 2022 US$ | Argentina |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Argentina or Nepal?
- Argentina, at 1,547 constant 2022 US$ against 1,526 constant 2022 US$ in Nepal as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Argentina and Nepal?
- 21 constant 2022 US$, with Argentina ahead.
- How many years of comparable data are there for Argentina and Nepal?
- 7 years are reported by both, from 2018 to 2024.
- How do Argentina and Nepal rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Argentina ranks 31st and Nepal ranks 33rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.